Mark:

QUREDOSE

Status Date:

08-01-2023

Registration Number:

7123802

Goods and Services:

Viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical products for the treatment of viral diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy, namely, biological preparations for medical diagnostic or treatment use; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing, namely, reagents for medical use; pharmaceutical preparations, vaccines, prophylaxis products and other products for use in nucleic acid-based therapy, gene therapy and cell therapy Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; Consultancy in the field of pharmaceutics Research, product development and consultancy in the field of biotechnology, biologic pharmaceutical preparations, medical science, chemistry and biochemistry; Research and product development in the field of pharmaceutics

Class:

Medical services

Published for Opposition Date:

02-28-2023

Mark Drawing Status:

Standart Character Mark

Business Name:

WOMBLE BOND DICKINSON (US) LLP